Gain Therapeutics, Inc. 8-K

What Happened
Gain Therapeutics, Inc. (NASDAQ: GANX) announced and filed a Current Report on Form 8-K on March 18, 2026 to disclose a press release pursuant to Regulation FD. The press release is attached to the filing as Exhibit 99.1 and is incorporated by reference. The filing also includes the cover page interactive data file (Exhibit 104).

Key Details

• Filing date: March 18, 2026.
• Form 8-K items reported: Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events).
• Exhibit included: 99.1 — Press Release dated March 18, 2026; Exhibit 104 — Inline XBRL cover page file.
• This Form 8-K furnishes a press release; it does not itself present earnings, financial statements, or management changes.

Why It Matters
A Regulation FD disclosure filing signals the company has released information it considers material to investors. Retail investors should read the attached press release (Exhibit 99.1) for the substantive update and monitor subsequent SEC filings for any related financial results or corporate developments. This 8-K only documents the company’s public disclosure — it does not by itself change earnings, leadership, or transaction status.